dc.contributor.author | Anak, Sema | |
dc.contributor.author | Yalman, Nevin | |
dc.contributor.author | Bilgen, Hülya | |
dc.contributor.author | Sepet, Elif | |
dc.contributor.author | Deviren, Ayhan | |
dc.contributor.author | Gurtekin, Basak | |
dc.contributor.author | Tunca, Fatih | |
dc.contributor.author | Basaran, Bora | |
dc.date.accessioned | 2020-10-06T09:50:44Z | |
dc.date.available | 2020-10-06T09:50:44Z | |
dc.date.issued | 2020 | en_US |
dc.identifier.citation | Anak, S., Bilgen, H., Yalman, N., Sepet, E., Deviren, A., Gurtekin, B., Tunca, F., ... Basaran, B. (June 01, 2020). Squamous cell carcinoma development in Fanconi anemia patients who underwent hematopoietic stem cell transplantation. Pediatric Transplantation, 24 (4). DOI: https://doi.org/10.1111/petr.13706 | en_US |
dc.identifier.issn | 1397-3142 | |
dc.identifier.issn | 1399-3046 | |
dc.identifier.uri | https://doi.org/10.1111/petr.13706 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12780/131 | |
dc.description.abstract | We examined SCC development of 24 FA patients, who received HSCT from HLA-matched relatives. In our BMT center, we applied low-dose CY + LFI + ATG (n:13) as conditioning regimen for FA patients between 1992 and 1999, and CY + BU + ATG (n:11) between 1999 and 2002. The aim of this study was to investigate SCC development after HSCT and examine features of the follow-up patients. The 10-year overall survival (OS) of the group with LFI + regimen was 43%, whereas the group without LFI regimen was 60%. There was a statistically significant relationship between infections (viral/bacterial) and overall survival (Fisher's Exact test P < .001). Five out of 13 long-term (>1 year) surviving patients developed SCC in the HNSCC (n:4) and esophagus (n:2) region (a patient with oral SCC developed a second primary esophageal SCC). The SCC rate in our FA patients was 38%, four of the SCC patients were transplanted with irradiation used conditioning regimens, three of them had acuteGvHD (Grade II-III), only one developed chronic GvHD. The interval between HSCT and SCC diagnosis was median 13 (range 6-18) years, the age for the development of cancer was median 21 (range 15-32) years. Survival after SCC was low, median 6 months (range 6-12), due to delayed SCC diagnosis, tumor progression under therapy and treatment-related toxicities of the usually reduced RT and/or CT. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | WILEY | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Fanconi Anemia | en_US |
dc.subject | Gvhd | en_US |
dc.subject | Hematopoietic Stem Cell Transplantation | en_US |
dc.subject | Squamous Cell Carcinoma | en_US |
dc.title | Squamous cell carcinoma development in Fanconi anemia patients who underwent hematopoietic stem cell transplantation | en_US |
dc.type | article | en_US |
dc.contributor.department | İstanbul Kent Üniversitesi, Fakülteler, Diş Hekimliği Fakültesi, Klinik Bilimler Bölümü | en_US |
dc.contributor.institutionauthor | Sepet, Elif | |
dc.identifier.volume | 24 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 1 | en_US |
dc.identifier.endpage | 5 | en_US |
dc.relation.journal | Pediatric Transplantation | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |